Sarah Belliotti
Obstetrics & Gynecology · East Amherst, NYNPI 1801258769
Payments from drug & device makers
Across 299 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$610
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$561
- AbbVie$520
- Organon$383
- Medical Device Business Services, Inc.$325
- Astellas Pharma US Inc$317
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,68995%
- Education$3255%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mayne Pharma Commercial LLC | 36 | $610 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $561 |
| AbbVie | 29 | $520 |
| Organon | 7 | $383 |
| Medical Device Business Services, Inc. | 1 | $325 |
| Astellas Pharma US Inc | 16 | $317 |
| Exeltis, USA Inc. | 15 | $316 |
| Therapeuticsmd, Inc. | 22 | $284 |
| Daiichi Sankyo Inc. | 11 | $255 |
| Exact Sciences | 9 | $220 |
| Pfizer | 12 | $200 |
| Agile Therapeutics, Inc. | 11 | $197 |
| Sumitomo Pharma America, Inc. | 9 | $172 |
| Amgen | 10 | $162 |
| Novo Nordisk | 8 | $153 |
| Currax Pharmaceuticals LLC | 7 | $118 |
| Biogen | 5 | $106 |
| Gilead | 4 | $101 |
| Mylan Pharmaceuticals Inc. | 5 | $96 |
| Shield Therapeutics Inc | 5 | $96 |
| Myovant Sciences Inc. | 6 | $91 |
| Bayer | 5 | $84 |
| Medela LLC | 1 | $75 |
| Coopersurgical, Inc. | 4 | $72 |
| Millicent US Inc | 3 | $66 |
| Dexcom, Inc. | 2 | $54 |
| Merck | 2 | $50 |
| Avion Pharmaceuticals | 3 | $50 |
| Evofem Biosciences, Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Seqirus USA Inc | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Ascend Therapeutics US, LLC | 1 | $21 |
| Roche Diagnostics Corporation | 1 | $20 |
| Si-bone, Inc. | 1 | $19 |
| Covidien LP | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Meditrina | 1 | $14 |
| Urovant Sciences Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JADA SYSTEM$257
How this compares
$6,014 in reported general payments places this provider in the 90th percentile of 2,673 obstetrics & gynecology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 22 | $2,870 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in East Amherst
- Marina FrimerBronx$8.5M
- Nicole NevadunskyBronx$2.5M
- Jin Hee KimNew York$1M
- Carolyn WesthoffNew York$935K
- Mary PolanNew York$862K
- Jessica AtrioBronx$752K
- Mark MartensAuburn$561K
- Steven GoldsteinNew York$557K
- Sharifa FaziliClarence$430K
- Dhruv AgneshwarJohnson City$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.